KRAS and cancer: The therapeutic potential of targeting mKRAS as a cancer neoantigen was highlighted in a case report demonstrating clinical benefit in a patient with KRAS G12D metastatic CRC following the adoptive transfer of KRAS G12D-specific T cells restricted to HLA-C*08:0222.